ZIM Laboratories Limited has successfully completed a significant preferential share allotment, with its Board of Directors approving the allocation of 47,64,497 equity shares to Florintree Trinex LLP on March 13, 2026. This strategic capital raising exercise demonstrates the company's continued efforts to strengthen its financial position and attract institutional investment.

Share Allotment Details

The preferential issue was executed on a private placement basis for cash consideration, with each equity share priced at ₹73.46. This pricing includes a substantial premium of ₹63.46 per share over the face value of ₹10.00. The transaction structure reflects strong investor confidence in the pharmaceutical company's growth prospects.

Capital Structure Impact

The successful completion of this preferential allotment has resulted in a significant expansion of ZIM Laboratories' equity base. The company's paid-up equity share capital has increased substantially, reflecting the infusion of fresh capital from the institutional investor.

Investor Shareholding

Florintree Trinex LLP, a limited liability partnership registered under the Limited Liability Partnership Act, 2008, has emerged as a significant stakeholder in ZIM Laboratories through this transaction. The investor, belonging to the non-promoter group, now holds a meaningful equity position in the company.

Regulatory Approvals and Compliance

The transaction received necessary regulatory clearances, with both the National Stock Exchange of India Limited and BSE Limited providing in-principle approval on February 27, 2026. The allotted equity shares will rank pari-passu in all respects with the existing equity shares of the company, ensuring equal rights and privileges for the new investor.

The Board meeting, which commenced at 11:30 a.m. and concluded at 2:15 p.m. on March 13, 2026, formalized the allotment process in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This preferential issue represents a significant milestone in ZIM Laboratories' capital raising strategy and positions the company for continued growth in the pharmaceutical sector.

Zim laboratories has received regulatory approval from the Dubai Multi Commodities Centre Authority (DMCC Authority) for the closure of its step-down subsidiary ZIM Laboratories Middle East DMCC (ZIM DMCC), effective February 23, 2026. The company announced this development through a regulatory filing to the stock exchanges, marking the completion of a key regulatory milestone in the subsidiary closure process.

Regulatory Approval Details

The DMCC Authority has formally approved the dissolution of ZIM DMCC, a step-down subsidiary of ZIM Laboratories Limited. This approval represents the final regulatory clearance required for the subsidiary's closure, which was initially approved by the company's Board of Directors.

Timeline of Events

The closure process began with the company's Board of Directors approving the step-down subsidiary's closure on August 7, 2025. The company had disclosed this board approval to the stock exchanges as part of its regulatory compliance obligations. The recent DMCC Authority approval represents the culmination of this closure process, providing the necessary regulatory clearance for the subsidiary's dissolution.

Compliance and Disclosure

ZIM Laboratories has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both BSE Limited and the National Stock Exchange of India Limited about the DMCC Authority's approval through formal intimation dated February 23, 2026.

The regulatory filing was signed by Piyush Nikhade, Company Secretary and Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements. This disclosure maintains transparency with stakeholders regarding the subsidiary's closure and its regulatory approval status.